These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 29280989)

  • 1. Design, Synthesis, and Biological Evaluation of Novel 1,3,4-Thiadiazole Derivatives as Potential Antitumor Agents against Chronic Myelogenous Leukemia: Striking Effect of Nitrothiazole Moiety.
    Altıntop MD; Ciftci HI; Radwan MO; Sever B; Kaplancıklı ZA; Ali TFS; Koga R; Fujita M; Otsuka M; Özdemir A
    Molecules; 2017 Dec; 23(1):. PubMed ID: 29280989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
    Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
    J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and biological activity of phenyl-pyrazole derivatives as BCR-ABL kinase inhibitors.
    Hu L; Zheng Y; Li Z; Wang Y; Lv Y; Qin X; Zeng C
    Bioorg Med Chem; 2015 Jul; 23(13):3147-52. PubMed ID: 26022079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.
    Ciftci HI; Ozturk SE; Ali TFS; Radwan MO; Tateishi H; Koga R; Ocak Z; Can M; Otsuka M; Fujita M
    Biol Pharm Bull; 2018 Apr; 41(4):570-574. PubMed ID: 29386476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Docking, G-QSAR Studies, Synthesis and Anticancer Screening of Some New 2-Phenazinamines as Bcr-Abl Tyrosine Kinase Inhibitors.
    Kale MA; Sonwane GM
    Curr Drug Discov Technol; 2020; 17(2):213-224. PubMed ID: 30210004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
    Huang WS; Metcalf CA; Sundaramoorthi R; Wang Y; Zou D; Thomas RM; Zhu X; Cai L; Wen D; Liu S; Romero J; Qi J; Chen I; Banda G; Lentini SP; Das S; Xu Q; Keats J; Wang F; Wardwell S; Ning Y; Snodgrass JT; Broudy MI; Russian K; Zhou T; Commodore L; Narasimhan NI; Mohemmad QK; Iuliucci J; Rivera VM; Dalgarno DC; Sawyer TK; Clackson T; Shakespeare WC
    J Med Chem; 2010 Jun; 53(12):4701-19. PubMed ID: 20513156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents.
    Radi M; Crespan E; Botta G; Falchi F; Maga G; Manetti F; Corradi V; Mancini M; Santucci MA; Schenone S; Botta M
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1207-11. PubMed ID: 18078752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
    Kumar H; Raj U; Gupta S; Varadwaj PK
    J Biomol Struct Dyn; 2016 Oct; 34(10):2171-83. PubMed ID: 26479578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
    Xu F; Shi X; Li S; Cui J; Lu Z; Jin Y; Lin Y; Pang J; Pan J
    Bioorg Med Chem; 2010 Mar; 18(5):1806-15. PubMed ID: 20149665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML).
    Liu F; Wang B; Wang Q; Qi Z; Chen C; Kong LL; Chen JY; Liu X; Wang A; Hu C; Wang W; Wang H; Wu F; Ruan Y; Qi S; Liu J; Zou F; Hu Z; Wang W; Wang L; Zhang S; Yun CH; Zhai Z; Liu J; Liu Q
    Oncotarget; 2016 Jul; 7(29):45562-45574. PubMed ID: 27322145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Virtual Screening Approach for the Identification of High Affinity Small Molecules Targeting BCR-ABL1 Inhibitors for the Treatment of Chronic Myeloid Leukemia.
    Sharda S; Sarmandal P; Cherukommu S; Dindhoria K; Yadav M; Bandaru S; Sharma A; Sakhi A; Vyas T; Hussain T; Nayarisseri A; Singh SK
    Curr Top Med Chem; 2017; 17(26):2989-2996. PubMed ID: 28828991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome-positive (Ph+) leukemias harboring the T315I mutation.
    Mian AA; Rafiei A; Haberbosch I; Zeifman A; Titov I; Stroylov V; Metodieva A; Stroganov O; Novikov F; Brill B; Chilov G; Hoelzer D; Ottmann OG; Ruthardt M
    Leukemia; 2015 May; 29(5):1104-14. PubMed ID: 25394714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel Bcr-Abl inhibitors with diacylated piperazine as the flexible linker.
    Pan X; Dong J; Shi Y; Shao R; Wei F; Wang J; Zhang J
    Org Biomol Chem; 2015 Jul; 13(25):7050-66. PubMed ID: 26052668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
    Elgehama A; Chen W; Pang J; Mi S; Li J; Guo W; Wang X; Gao J; Yu B; Shen Y; Xu Q
    Cancer Lett; 2016 Mar; 372(1):82-8. PubMed ID: 26721204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A derivative of epigallocatechin-3-gallate induces apoptosis via SHP-1-mediated suppression of BCR-ABL and STAT3 signalling in chronic myelogenous leukaemia.
    Jung JH; Yun M; Choo EJ; Kim SH; Jeong MS; Jung DB; Lee H; Kim EO; Kato N; Kim B; Srivastava SK; Kaihatsu K; Kim SH
    Br J Pharmacol; 2015 Jul; 172(14):3565-78. PubMed ID: 25825203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
    Roy M; Sarkar R; Mukherjee A; Mukherjee S
    Chem Biol Interact; 2015 Dec; 242():195-201. PubMed ID: 26456889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, Synthesis and Biological Evaluation of a Novel Series of Thiadiazole- Based Anticancer Agents as Potent Angiogenesis Inhibitors.
    Altuğ-Tasa B; Kaya-Çavuşoğlu B; Koparal AT; Turan G; Koparal AS; Kaplancıklı ZA
    Anticancer Agents Med Chem; 2021; 21(15):2041-2049. PubMed ID: 33390125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and Evaluation of a Series of 1,3,4-Thiadiazole Derivatives as Potential Anticancer Agents.
    Altıntop MD; Sever B; Özdemir A; Ilgın S; Atlı Ö; Turan-Zitouni G; Kaplancıklı ZA
    Anticancer Agents Med Chem; 2018; 18(11):1606-1616. PubMed ID: 29745341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
    Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
    Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.